Fibroblast growth factor 23 and the future of phosphorus management

Myles Wolf*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Purpose of review: To present emerging data on the role of fibroblast growth factor 23 (FGF23) in mineral metabolism and adverse outcomes in chronic kidney disease (CKD). Recent findings: FGF23 regulates phosphorus and vitamin D metabolism. Its levels increase progressively beginning in early CKD, presumably as a physiological adaptation to maintain normal serum phosphate levels or normal phosphorus balance. FGF23 promotes phosphaturia and decreases production of calcitriol. Recent studies suggest that increased FGF23 is associated with mortality, left ventricular hypertrophy, endothelial dysfunction and progression of CKD. These results were consistently independent of serum phosphate levels. Summary: FGF23 is emerging as a novel and exciting biomarker that may help identify which CKD patients might benefit most from aggressive management of disordered phosphorus metabolism. Future studies should determine whether increased FGF23 levels exert direct end-organ toxicity, such as in the heart, vessels and kidneys.

Original languageEnglish (US)
Pages (from-to)463-468
Number of pages6
JournalCurrent opinion in nephrology and hypertension
Issue number6
StatePublished - Nov 2009
Externally publishedYes


  • 1,25-dihydroxyvitamin O
  • Cardiovascular disease
  • Fibroblast growth factor 23
  • Mortality
  • Phosphorus

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine


Dive into the research topics of 'Fibroblast growth factor 23 and the future of phosphorus management'. Together they form a unique fingerprint.

Cite this